Why the study?
What are the pathophysiological mechanisms, clinical implications, and potential therapies regarding epicardial adipose tissue in atrial fibrillation?
What are the pathophysiological mechanisms, clinical implications, and potential therapies regarding epicardial adipose tissue in atrial fibrillation?
This review highlights the association between epicardial adipose tissue and adverse outcomes in atrial fibrillation, suggesting weight loss and GP ablation as potential therapeutic targets.
Answers are grounded in this paper and cite their sources.
Does not support routine epicardial adipose tissue assessment in AF; hypothesis-generating for weight loss or ablation strategies.
Notably, EAT accumulation seems to be associated with stroke and adverse cardiovascular outcomes in AF. Weight loss, specific medications and ablation of ganglionated plexi (GP) seem to be potential therapies in this setting.
No takes yet. Share an insight, caveat, or question.
Goudis et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: